Highlighting the clinical significance of our findings, these results are in accordance with our observation that high TROP2 expression correlates with poor prognosis in cohorts of prostate cancer patients, particularly in patients with low (Gleason 6) grade tumors. The gene discussed is TACSTD2; the disease is prostate cancer.